Vascular Biogenics Ltd. Banner Image

Vascular Biogenics Ltd. has reached its limit for free report views

Work for Vascular Biogenics Ltd.? Upgrade Your Profile and unlock all your annual reports.

Vascular Biogenics Ltd.

  • Ticker VBLT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Vascular Biogenics Ltd. Logo Image
  • 11-50 Employees
  • Based in Modiin, Israel
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focusMore on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks.
Vascular Biogenics Ltd.

Most Recent Annual Report

Vascular Biogenics Ltd. MOST RECENT 2019 Annual Report

Report Locked. Vascular Biogenics Ltd. has reached its limit for free report views.

Older/Archived Annual Reports